MDMA
News You Might Have Missed: April 10th, 2023
The article News You Might Have Missed: April 10th, 2023 was originally published on Microdose.
Welcome to the News You Might Have Missed, a weekly roundup…
The article News You Might Have Missed: April 10th, 2023 was originally published on Microdose.
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed.
Ketamine Wellness Centers Re-Opening? Delic Holdings Signs LOI with Peter/PetraMD
This week we got news that Ketamine Wellness Centers might have a renewed sign of life. Peter/PetraMD, the largest online provider of hormone therapy for men and women in the United States, has announced the intent to acquire Ketamine Wellness Centers.
“We understand telemedicine, and we understand what it is our patients want—they want to feel better, they want to get better, and they want to live better lives. This acquisition would definitely further our mission to provide affordable and equitable access to healthcare across the nation”
MindBio Therapeutics Receives Conditional Approval from the Canadian Securities Exchange for Listing
MindBio Therapeutics, a clinical-stage drug development company focused on microdosing research and trials, has announced its approval for listing on the CSE under the ticker symbol MBIO.
The company’s flagship program is a Phase 1 clinical trial for Microdosing LSD. Last year, MindBio completed its Phase 1 clinical trial, the largest safety study of its kind.
Beckley Psytech Launches Phase 2a study of 5-MeO-DMT for Alcohol Use Disorder
Beckley Psytech is moving its 5-MeO-DMT program forward, announcing a new Phase IIa study investigating its lead candidate, BPL-003, as a potential treatment for alcohol use disorder (AUD).
Beckley Psytech’s Phase IIa study, taking place at King’s College Hospital in London, will explore the safety, efficacy and pharmacokinetics of BPL-003 in patients diagnosed with alcohol use disorder (AUD).
MAPS Announces Positive Topline Results from Follow-Up Study
More good news from MAPS as it moves its trials through the final approval steps. These long-term follow-up result should only bolster their case to the FDA.
Amy Emerson, chief executive officer, MAPS PBC: “These results are consistent with previously published Phase 2 data demonstrating the sustained effect of MDMA-assisted therapy at least 12 months following treatment and suggest the acute treatment effect could last even longer.”
Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”). AGN Neuro also reports that the safety review committee has approved moving the study forward with the final cohort at an escalated dose after observing no safety or tolerability issues.
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
mdma lsd ketamine dmt n-dimethyltryptamine dimethyltryptamine psychedelic therapeutics microdosing therapy cse delic holdings delic algernon beckley psytech beckley fda research
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment